Medical Information Only. Consult your healthcare provider before enrolling in any clinical trial.
Michigan: below-average open trial sites
1,648 of 4,790 in-state trials are recruiting (34%); below the 37% national average by 3 percentage points.
According to ClinicalTrials.gov-derived indexes, Michigan sits in the upper half of US states by in-state trial count (#14 of 52 states by registered in-state trial count).
Michigan: 4,790 US clinical trials with in-state sites, 1,648 recruiting.
Michigan has 4,790 registered US clinical trials with a study site in-state, 1,648 of them currently recruiting (below the 37% national average by 3 percentage points). 964 of these trials are in Phase 3 (late-stage) and 1,052 in Phase 2. The most frequently studied condition in Michigan is Breast Cancer, with 99 linked trials.
Mid-pack research density
Michigan sits in the upper half of the state corpus, so volume is meaningful but not hub-scale. Use condition and sponsor rollups below to see what drives the in-state mix.
Below-average open enrollment
Michigan still shows 1,648 recruiting of 4,790 in-state trials (34% open), but below the 37% national average by 3 percentage points, so archived statuses weigh heavier than the national baseline.
- 34%
- open (below national share)
- 1,648
- still recruiting despite cool share
- 1,052
- Phase 2 rows in this footprint
- 99
- top: Breast Cancer
Recruiting share is below the 37% national average by 3 percentage points. Counts include every study with at least one recorded site in the state. Registry reference only, not medical advice.
Michigan vs all states by indexed in-state trial count
Where this state's ClinicalTrials.gov site count sits among every state with at least one listed trial (coverage density, not care quality)
4,790 Top 27% more indexed trials than 73% of 52 states
States, banded by indexed in-state trial count
Each bar is a band; taller bars hold more states. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov · 2026-08-08
Key findings
What ClinicalTrials.gov does not surface for Michigan on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Michigan open-enrollment share sits below the national baseline.
1,648 of 4,790 in-state trials (34.4%) are recruiting, against 37% nationally (-2.6 percentage points). Counts include every study with at least one recorded site in the state.
-
Michigan trial sites spread across 8 city hubs.
Ann Arbor lists 1,925 of 4,790 in-state trials (40.2%) across 445 named facilities. Cities need five or more listed trials to appear here; locations are as filed by sponsors.
-
Breast Cancer is the most-studied condition in Michigan.
99 of 4,790 in-state trials (2.1%) list Breast Cancer. That is a local concentration figure, not a national disease ranking.
-
Michigan sponsorship is fragmented across many organizations.
University of Michigan appears on 433 of 4,790 in-state trials (9%). Sponsor identity is as filed on ClinicalTrials.gov.
-
2,031 Michigan trials carry a completed status.
2,031 of 4,790 (42.4%) are completed. The open share above is the remainder that still lists recruiting.
By Status
| Status | Trial count |
|---|---|
| Completed | 2,031 |
| Recruiting | 1,648 |
| Active | 1,111 |
By Phase
| Phase | Trial count |
|---|---|
| NA | 1,096 |
| Phase 2 | 1,052 |
| Phase 3 | 964 |
| Phase 1 | 876 |
| Phase 4 | 191 |
| Early Phase 1 | 21 |
Top Conditions
Top Sponsors
Where trials run in Michigan
Ann Arbor carries 1,925 of Michigan's 4,790 indexed trials (40%) across 445 named sites, ahead of Detroit at 1,584. 8 cities clear five listed trials, together naming 1,402 distinct sites.
| City | Trials | Listed sites |
|---|---|---|
| Ann Arbor | 1,925 | 445 |
| Detroit | 1,584 | 435 |
| Grand Rapids | 539 | 210 |
| Royal Oak | 191 | 70 |
| Farmington Hills | 136 | 62 |
| Troy | 115 | 64 |
| Lansing | 96 | 54 |
| Flint | 92 | 62 |
Distinct trials and named sites per city, as filed with ClinicalTrials.gov; cities under five trials omitted. Vintage 2026-08-08.
Open-share high
Michigan open-enrollment share is 34% (p76 of states with sites; national baseline 37%).
Michigan: open share sits in the high tercile of states
Sites spread across 8 cities with five or more listed trials, led by Ann Arbor (1,925, 40% of the state total) and Detroit (1,584), together naming 1,402 distinct research locations.
Phase mix: 964 Phase 3 vs 1,052 Phase 2 (balanced across stages).
Top condition: Breast Cancer (99 trials); top sponsor University of Michigan (433).
high-volume · high-open figures (4,790 trials · 34% open) describe registry geography under the open-share high read, not clinic capacity or protocol fit. Confirm status on ClinicalTrials.gov before acting.
States near Michigan on open-enrollment share
Cross-state peers under the open-share high read (high-volume · high-open), not the same-state browse list.
Similar high-volume hubs (± open share)
Similar high-open peers (± trial volume)
- Oklahoma · 34% recruiting · 1,061 trials
- Rhode Island · 34% recruiting · 753 trials
- South Carolina · 35% recruiting · 1,706 trials
- Pennsylvania · 34% recruiting · 6,946 trials
- New York · 35% recruiting · 10,554 trials